INOZYME PHARMA, INC. — Operating Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a1aad076-2772-444d-8252-11366cbc17f9/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-104.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-035940 |
| FY 2023 | $-75.6M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-029673 |
| FY 2022 | $-68.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-009053 |
| FY 2021 | $-56.6M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-003789 |
| FY 2020 | $-57.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015250 |
| FY 2019 | $-20.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-015250 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).